ERBB2 and gastric cancer: HER2 overexpression in GC (7–34%), which appeared to be associated with poorer prognosis, is now linked to improved outcomes among these patients, thanks to the use of trastuzumab, a mAb directed against the extracellular HER2 domain [9].